title: Intracerebroventricularly administered lipopolysaccharide enhances spike-wave discharges in freely moving WAG/Rij rats.
abstract: Peripheral lipopolysaccharide (LPS) injection enhances spike-wave discharges (SWDs) in the genetic rat model of absence epilepsy (Wistar Albino Glaxo/Rijswijk rats: WAG/Rij rats) parallel with the peripheral proinflammatory cytokine responses. The effect of centrally administered LPS on the absence-like epileptic activity is not known, however despite the important differences in inflammatory mechanisms. To examine the effect of centrally administered LPS on the pathological synchronization we intracerebroventricularly (i.c.v.) injected LPS into WAG/Rij rats and measured the number and duration of SWDs. I.c.v. injected LPS increased the number and duration of SWDs for 3h, thereafter, a decrease in epileptic activity was observed. To further investigate the nature of this effect, a non-steroid anti-inflammatory drug (indomethacin; IND) or a competitive N-methyl-d-aspartate (NMDA) receptor antagonist (2-amino-5-phosphonopentanoic acid; AP5) was injected intraperitoneally (i.p.), preceding the i.c.v. LPS treatment. IND abolished the i.c.v. LPS induced changes in SWDs, while AP5 extended it for 5h. As control treatments, both IND and AP5 application by themselves decreased the number of SWDs for 2 and 3h, respectively. Our results show that centrally injected LPS, likewise the peripheral injection, can increase the number and duration of SWDs in the WAG/Rij rat, and the effect invoke inflammatory cytokines as well as excitatory neurotransmitters.
authors.affiliation: Department of Zoology, University of West Hungary, Savaria Campus, Szombathely, Károlyi Gáspár tér 4, 9700, Hungary. zskovacs@ttk.nyme.hu
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Kovács
authors.forename: András
authors.initials: A
authors.lastname: Czurkó
authors.forename: Katalin A
authors.initials: KA
authors.lastname: Kékesi
authors.forename: Gábor
authors.initials: G
authors.lastname: Juhász
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001831:Body Temperature / Q000187:drug effects; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D004569:Electroencephalography; D004827:Epilepsy / Q000503:physiopathology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D057967:Infusions, Intraventricular; D008070:Lipopolysaccharides / Q000008:administration & dosage* / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology*; D009424:Nervous System Physiological Phenomena / Q000187:drug effects*; D051381:Rats; D011919:Rats, Inbred Strains; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D018691:Excitatory Amino Acid Antagonists; D008070:Lipopolysaccharides; D016194:Receptors, N-Methyl-D-Aspartate; D015763:2-Amino-5-phosphonovalerate; D007213:Indomethacin